Etelcalcetide Injection (Parsabiv)

Parsabiv (etelcalcetide) is covered for adult CKD patients with secondary hyperparathyroidism who are on hemodialysis and is excluded for non-dialysis/peritoneal dialysis patients or when used with/within 7 days of cinacalcet. Approval requires documentation of hemodialysis, corrected serum calcium ≥7.5 mg/dL, no signs/symptoms of hypocalcemia, PTH ≥300 pg/mL for initial (≥100 pg/mL for reauthorization), dosing ≤15 mg IV bolus up to three times weekly at end of dialysis, and is authorized for up to 12 months.

"Has no signs or symptoms of hypocalcemia (e."

Sign up to see full coverage criteria, indications, and limitations.